The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

Between 30-50% of adults with hypertension have OSA, and this number increases to between 70-80% in adults with resistant hypertension. Additionally, untreated moderate-to-severe OSA increases the ...

From sleep apnea-fighting mattresses to smart rings that play lullabies, the best sleep tech from Day 1 of CES 2025 ...

Truly, you'll find me snuggled up in my bed whenever the opportunity arises, and I'm always down to go try some delicious new ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

Gal-475 is under clinical development by Neurim Pharmaceuticals and currently in Phase I for Sleep Apnea. According to GlobalData, Phase I drugs for Sleep Apnea have a 96% phase t ...

( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...

This article presents evidence that he suffered from obstructive sleep apnea, manifested by excessive daytime somnolence, snoring, systemic hypertension and, perhaps, cognitive and psychosocial ...

(HealthDay News) — The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA). In a news ...

Until now, OSA treatment has focused on mechanical support during sleep in the form of positive airway ... option for certain patients with obstructive sleep apnea," said Sally Seymour, MD ...